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ABSTRACT
Pediatric acute myeloid leukemia (AML) is a heterogeneous disease with respect 
to biology as well as outcome. In this study, we investigated whether known biological 
subgroups of pediatric AML are reflected by a common microRNA (miRNA) expression 
pattern. We assayed 665 miRNAs on 165 pediatric AML samples. First, unsupervised 
clustering was performed to identify patient clusters with common miRNA expression 
profiles. Our analysis unraveled 14 clusters, seven of which had a known (cyto-)genetic 
denominator. Finally, a robust classifier was constructed to discriminate six molecular 
aberration groups: 11q23-rearrangements, t(8;21)(q22;q22), inv(16)(p13q22), t(15;17)
(q21;q22), NPM1 and CEBPA mutations. The classifier achieved accuracies of 89%, 95%, 
95%, 98%, 91% and 96%, respectively. Although lower sensitivities were obtained 
for the NPM1 and CEBPA (32% and 66%), relatively high sensitivities (84%−94%) 
were attained for the rest. Specificity was high in all groups (87%−100%). Due to a 
robust double-loop cross validation procedure employed, the classifier only employed 47 
miRNAs to achieve the aforementioned accuracies. To validate the 47 miRNA signatures, 
we applied them to a publicly available adult AML dataset. Albeit partial overlap of 
the array platforms and molecular differences between pediatric and adult AML, the 
signatures performed reasonably well. This corroborates our claim that the identified 
miRNA signatures are not dominated by sample size bias in the pediatric AML dataset. 
In conclusion, cytogenetic subtypes of pediatric AML have distinct miRNA expression 
patterns. Reproducibility of the miRNA signatures in adult dataset suggests that the 
respective aberrations have a similar biology both in pediatric and adult AML.
INTRODUCTION
Currently, pediatric AML patients are stratified into 
risk categories according to response to induction therapy 
and genetic abnormalities, as defined in the WHO 2008 
classification [1]. Although patient outcome has improved 
over the past decades, overall survival rates are 60–70% 
and the relapse rate is still high [2–4]. To further improve 
patient outcome, biological studies that aim to identify 
leukemogenic drivers and/or signaling pathways that 
can be directly targeted are needed. This is necessary as 
further intensification of chemotherapy may cause higher 
frequency of early and late side effects, including therapy-
related mortality [5]. Alternatively, patient outcome may 
be improved by refining the risk-group classification and 
identify uniform subgroups utilizing (epi-) genetic and 
molecular aberrations, which may also contribute to the 
design of targeted therapy [6]. Identification of hallmark 
aberrations and their accompanying molecular targets for 
the 15–20% of unclassified pediatric AML patients is the 
subject of many ongoing biological studies [7]. 
Mutations in AML can be categorized into Type I 
and Type II classes [42]. Type I aberrations occur in genes 
involved in cell proliferation and survival (e.g., FLT3, 
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KIT, NRAS and and TP53) while Type II aberrations 
lead to impaired differentiation. Examples of these are 
PML-RARα, MLL-rearrangements and CBFB-MYH11.
MiRNAs - circa 22 nucleotide long non-coding 
RNAs - influence gene expression by suppressing the 
translation of genes that have sequences complementary 
to the miRNA in their 3′UTR. Since a miRNA can 
target multiple genes, it therefore can influence many 
physiological processes like apoptosis, proliferation, 
differentiation, and ageing as well as hematopoietic 
differentiation [8–13]. The epigenetic effect of miRNA on 
gene expression contributes to leukemogenesis through 
interaction with tumor suppressor genes that are involved 
in cell proliferation and differentiation [10, 14–17]. 
Although cancer-promoting miRNAs have been described 
in adult AML, there are unmet demands for studies on 
role of miRNA in pediatric AML [18–21]. Zhang et al. 
described miR-expression differences between FAB-M1, 
FAB-M2 and FAB-M3 groups in pediatric AML [21]. 
In our previous work, we demonstrated the non-random 
distribution of miR-29a, miR-155, and miR-196a/b 
expressions between clinically relevant genetic entities of 
pediatric AML [18]. Daschkey et al. performed clustering 
on pediatric samples with t(8;21), t(15;17) and MLL-
rearrangements using their miR-expression profiles [19]. 
We also showed that inv(16) and other genetic aberrations 
in pediatric AML have specific miR-expression profiles. 
Furthermore, low expression of the miR-9 was identified 
to act as a tumor-suppressor in cooperation with let-7 
family members in a stringent cell-context dependent 
manner in pediatric AML samples with t(8;21) [20]. In 
another it has been identified that high expression of the 
miR-99a, miR-125b and let-7c in pediatric AML with FAB 
M7 phenotype promoted leukemogenesis by switching 
the balance between TGFß and Wnt signaling [22]. 
However, so far, no study has been conducted to identify 
novel prognostic subgroups of pediatric AML based 
on the miRNA profiles. To address this, in the work 
we investigated, in a large cohort, whether genetic and 
molecular subtypes of childhood AML can be classified 
using their miRNA expression profiles.
RESULTS
Unsupervised clustering
We began by performing hierarchical clustering of 
patients using a subset of miRNAs. The miRNAs were 
selected if they were 6-fold higher or lower expressed 
than that of the geometric mean of the cohort in at least 
one patient sample. This resulted in selection of 563 out 
of 664 arrayed miRNAs. The clustering was performed 
using Pearson correlation as distance metric and Ward’s 
minimum variance as linkage. Clustering results are shown 
in Figure 1. The clusters subsequently were examined for 
the enrichment of cytogenetic and molecular aberrations, 
FAB-classification, and mean age and white blood cell 
count (Supplementary Table 1), separately. We observed 
that miRNAs expressions correlated with cytogenetic 
and molecular aberrations groups, especially with MLL-
rearrangements, NPM1 mutations, inv(16)(p13q22), 
t(8;21)(q22;q22), and t(15;17)(q21;q22). However, the 
clusters were not enriched for type I aberrations (FLT3-
ITD, FLT3-TKD, and mutations in WT1, NRAS, KRAS, 
PTPN11, and C-KIT).
The samples with MLL-rearrangements appeared 
to be separated into two sub-clusters: cluster 1 and 
cluster 9. But, this separation was not related to the MLL-
translocation partner. Majority of samples with NPM1-
mutations were located adjacent to the samples with MLL-
rearrangements in the cluster 2. Four samples with NPM1 
mutations were scattered in the cluster 1 (n = 1), cluster 3 
(n = 2) and cluster 8 (n = 1).
Fifty-three percent of the samples (n = 17) with 
inv(16)(p13q22) were found in the cluster 4 and the 
rest were scattered over 6 clusters. The samples with 
t(8;21)(q22;q22) grouped closely together in the cluster 
6 and the cluster 10, two cases were found in the 
heterogeneous cluster 5 that encompasses samples with 
various aberrations. We presumed that the distribution of 
samples with t(8;21)(q22;q22) in two sub-clusters might 
be due to differences in type I mutations or morphological 
features. However, no significant differences between 
these clusters were observed based on the afore-mentioned 
characteristics (Supplementary Table 2). All samples with 
CEBPA double mutations were clustered together with the 
t(8;21)(q22;q22) samples.
Eleven out of the twelve samples with t(15;17)
(q21;q22) were present in the cluster 11. We observed no 
enriched biological characteristic, e.g. type I aberration, of 
the outlying sample. 
The cluster 7 and 13 were consisted of > 65% of 
samples (n = 4 and n = 6) with “other” cytogenetics but 
no known common cytogenetic or molecular denominator 
was found. 
For the three cytogenetic groups, i.e. the t(7;12)
(q36;p13, t(8;16)(p11;p13), and NUP98-rearrangements, 
no homogeneous cluster was found. 
Classification of genetic and molecular subtypes
To investigate the potential of miRNAs in predicting 
known Type II aberration subtypes, we performed 
classification using samples with MLL-rearrangements, 
t(8;21)(q22;q22), inv(16)(p13q22), t(15;17)(q21;q22), 
CEBPA double mutations and NPM1 mutations. Subtypes 
selection was purely due to control sample sizes. We 
generated miRNA signatures specific to each genetic 
subtype using Support Vector Machine (SVM). As 
previously described, a double-loop-cross-validation 
(DLCV) strategy avoids over-fitting and leads to stable 
signatures with highest prediction accuracy [24]. Details 
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of about classification model construction steps are given 
in the Supplementary information.
The mean prediction accuracy of 100 double-
loop cross-validation (DLCV) runs in the second loop 
is given in Table 1. We observed that the classifier 
rendered high prediction sensitivities in the subtypes 
of MLL-rearrangements, t(8;21)(q22;q22), inv(16)
(p13q22) and t(15;17)(q21;q22), ranging from 84–94%. 
In the groups with CEPBA double mutations and NPM1 
mutations, however, low prediction sensitivities were 
observed (66% and 32%, respectively). The specificities 
in all subtypes were high (87–100%). The optimal set of 
47 miRNAs signatures and their expression relative to 
the other subtypes are given in Supplementary Table 4. It 
can be seen that high expression of miR-362-5p and low 
expression of miR-133a is specific for samples with MLL-
rearrangements, while high expression of miR-369-3p, 
miR-369-5p, miR-409-5p, miR-485-5p, miR-654-3p, and 
miR-654-5p is specific for samples with t(15;17). 
Samples with MLL-rearrangements were classified 
with 89% accuracy using 37 miRNA expression 
signatures; 14 miRNAs were highly expressed and 23 
were lowly expressed compared to the samples without 
MLL-rearrangements. Among the 23 downregulated 
miRNAs, seven are known tumor suppressors: let-7f, 
miR-126, miR-181a, miR-181c, miR-195, miR-26a, and 
miR-29a32. Two miRNAs were only used to classify 
MLL-rearranged samples: lowly expressed miR-133 and 
highly expressed miR-362-5p. Classification of samples 
with NPM1 mutations was achieved 91% accuracy by 
only using five miRNAs: let-7c, let-7f, and miR-196b 
were highly expressed and miR-126 and miR-320 lowly 
expressed. The samples carrying inv(16)(p13q22) were 
characterized by 17 miRs; three were lowly expressed, 14 
were highly expressed. 
Fourteen miRNAs were used to classify samples 
with t(8;21)(q22;q22). Among them, eight were lowly 
expressed and six were highly expressed. The 14 miRNA 
Figure 1: Unsupervised clustering of the pediatric AML samples using their miRNA profiles. This combination of heatmaps 
shows the miRNA expression profiles of 165 pediatric AML patients divided 14 clusters found through semi-unsupervised clustering based 
on miRNA expression of 563 miRs. The selected miRNAs provided the clearest division between clusters. Left-hand side: normalized 
miRNA expression values with green meaning down regulation and red up regulation. The rows were ordered based on the correlation plot on 
the right. Columns were ordered by hierarchical clustering. Right-hand side: Pairwise correlation between 165 pediatric patients with acute 
myeloid leukemia. The cells are colored by Pearson’s correlation coefficient values ranging from dark blue (negative correlation) to dark 
red (positive correlation). FAB-type, Karyotype, CEBPA mutation status, NPM1 mutation status, NUP98-rearrangements and MLL-PTD 
are plotted alongside the graph. For the clinical characteristic that have no plotted legend, green means the characteristic is absent, red 
means that it is present and white means that the sample was not tested for this characteristic.
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expression signature largely overlapped with the signature 
specific to inv(16) subtype. The classifier generated 18 
miRNA signatures specific to the samples with CEBPA 
double-mutations that resulted in classification accuracy 
of 96%. Among them 12 were lowly expressed and six 
highly expressed miRNAs. The samples carrying t(15;17)
(q21;q22) were classified with accuracy of 98% by 14 
upregulated miRs, of which six miRs, miR-369-3p, miR-
369-5p, miR-409-5p, miR-485-5p, miR-654-3p, and miR-
654-5p, were specific to this group.
Validation of the 47 miRNA signatures 
To examine the validity of the 47 miRNA signatures 
generated on the pediatric AML dataset, we test their 
prediction power using an independent dataset. Due to 
lack of a sufficiently large pediatric AML dataset, we used 
an adult AML dataset from Jongen-Lavrencic et al [42] 
instead. The t(15;17)(q21;q22) group was excluded from 
the analysis due to insufficient samples. Classification 
results are given in Table 2. Relatively high classification 
sensitivities were obtained in the t(8;21)(q22;q22), inv(16)
(p13q22), CEBPA double-mutations and NPM1 mutations 
groups (83%–100%), whereas, the MLL-rearrangements 
displayed a lower sensitivity (50%). Similar to the 
pediatric dataset, high specificities were obtained in all 
groups (84%–100%).
DISCUSSION
Unsupervised clustering using expression of 665 
human miRNAs revealed the discriminative power 
miRNA for samples with cytogenetic abnormalities, i.e. 
MLL-rearrangements, NPM1 mutations, inv(16)(p13q22), 
t(8;21)(q22;q22), and t(15;17)(q21;q22). Furthermore, 
classification of selected cytogenetic groups using only 47 
miRs resulted in high sensitivity. These results may reflect 
the relative homogeneous biology of these subtypes in 
terms of their miRNA profiles.
Our results are in line with previous study that 
reported strong miRNA signatures for pediatric AML 
carrying inv(16)(p13q22) and t(8;21)(q22;q22) [19]. 
Multiple studies on adult AML also reported predictive 
miRNA markers for t(15;17)(q21;q22) and the CBF-
leukemias [33–35]. One of the clusters showed in our 
study enriched for sample with NPM1 mutations (64%), 
indicating there is a NPM1 mutation specific miRNA 
expression profile, which concordant with studies on adult 
AML [36]. Interestingly, although NPM1 cases cluster 
together in unsupervised analysis, classification of these 
samples only resulted in sensitivity of 32%. This might be 
due to (a) the number of included samples; (b) cooperating 
genomic events that influence the miRNA profiles of 
the samples [43]. The MLL-rearranged specific miRNA 
Table 1: Classification results achieved on the pediatric AML dataset
(%) Sensitivity Specificity PPV NPV Accuracy 
MLL(n = 36) 93 87 79 97 89
t(8;21)(q22;q22)(n = 21) 94 95 84 99 95
inv(16)(p13q22)(n = 17) 84 97 86 97 95
t(15;17)(q21;q22)(n = 12) 85 100 97 98 98
CEPBA.dm(n = 11) 66 100 97 96 96
NPM1(n = 11) 32 98 46 93 91
Note: PPV- positive predictive value, NPV- negative predictive value.
Table 2: Validation of the 47 miRNA signatures, generated from the pediatric AML dataset, on the 
adult AML dataset 
(%) Sensitivity Specificity PPV NPV Accuracy 
MLL(n = 12) 50 100 100 95 95
t(8;21)(q22;q22)(n = 12) 100 100 100 100 100
inv(16)(p13q22)(n = 15) 100 100 100 100 100
CEPBA.dm(n = 16) 83 100 100 97 98
NPM1(n = 68) 100 84 88 100 93
Note: PPV- positive predictive value, NPV- negative predictive value.
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signatures, however, were not previously reported either 
in pediatric or in adult AML. 
To quantify the predictive power of miRNA 
expression in discriminating the cytogenetic subtypes 
in a supervised way, we performed classification using 
multiple well-known classification algorithms, which are 
given in the Supplementary Information. We observed 
that the classification accuracies are relatively uniform 
across algorithms. This corroborates our findings, and our 
original decision to use SVM as a classifier is free from 
selection bias.
Overall, classification accuracies using samples’ 
miRNA expression profiles were not exceeded that of the 
classification using gene expression profiles previously 
reported [24]. Superior performances of the mRNA-based 
classifier over the miRNA-based one have also been 
reported in two studies on adult AML [35, 37]. 
The power of our classifier might be further 
validated using an independent pediatric AML cohort. 
Unfortunately, currently datasets that can be used for 
validation are scarce. In this study, we were only able to 
validate out classifier with an adult AML dataset, which 
we think is the closest replication cohort [35–37]. 
Majority of the miRNAs reported here were 
overlapped with the ones mentioned by Jongen-Lavrencic 
et al: miR-485-5p for t(15;17)(q21;q22), miR-126*, miR-
196b, and miR-9 for t(8;21)(q22;q22), miR-126*, miR-30b, 
and miR-335 for inv(16)(p13q22), miR-149, miR-181a, 
miR-181c, miR-196b, and miR-9 for CEBPA double-
mutated cases. In a study on adults AML it has been 
reported that miRNAs could be used for class prediction of 
t(15;17)(q21;q22), t(8;21)(q22;q22) and inv(16)(p13q22) 
[35]. Li et al. used 7 miRNAs for class prediction of 
CBF-leukemia (inv(16)(p13q22) and t(8;21)(q22;q22) 
together), t(15;17)(q21;q22) and MLL-rearrangements, 
which resulted in an accuracy of > 94% in a cohort of 52 
adults using bead arrays [37]. We confirmed the potential 
of miR-126/miR-126* over expression in CBF leukemias. 
MiR-485-5p was the only miRNA used to classify 
both adult and pediatric AML samples with t(15;17) [35, 
37]. The MiR-485-5p is encoded on chromosome 14q32.31, 
and overexpression of several miRNAs located adjacent 
to each other on this location has been reported in adult. 
However, these miRNAs were not used for classifying 
the adult AML samples with t(15;17). Interestingly, the 
miRNA signatures specific to the t(15;17)(q21;q22) 
group are encoded on chromosome 14q32.31 [34]. The 
mechanism behind their overexpression and possible 
function in AML has not been elucidated yet. We believe 
findings might provide clues regarding the distinct biology 
of t(15;17)(q21;q22) positive AML.
Down regulation of miR-126, miR-196b, and miR-9 
was found in both pediatric and adult t(8;21)(q22;q22) 
AML. In our recent we showed that down regulated miR-9 
acts as a tumor suppressor in pediatric t(8;21)(q22;q22) 
AML and induced differentiation through targets HMGA2 
and LIN28B in cooperation with the let-7 family. It might 
be worthwhile to explore the therapeutic potential by 
ectopic expression of miR-9 in t(8;21)(q22;q22) positive 
AML [20]. 
The miR-126*, miR-30b, miR-30d, and miR-335 
were also used to classify adult AML samples with inv(16)
(p13q22) [35, 37]. It has been reported there were relationship 
between down regulation of miR-30b and overexpression of 
oncogene MYBL2, and poor prognosis [38].
While the miR-10a and miR-10b were used to 
classify adult AML saples with NPM1 mutations, neither 
of them was selected by our classifier when discriminating 
the samples with NPM1 mutations in our cohort [36, 39]. 
This might reflect the differences in leukemogenic 
pathways between children and adults or may be merely 
due to the method of miRNA-selection. In addition, the 
miRNA profiles of NPM1-mutated samples resemble the 
profiles of MLL-rearranged samples, which explain why 
these samples ended up in the same cluster. 
Expression of five miRNAs, miR-149, miR-181a, 
miR-181c, miR-196b, and miR-9, in pediatric AML 
samples with CEBPA mutations were also reported in 
adult AML case with CEBPA mutations [33, 35, 37, 40]. 
Over expressions of tumor suppressive miR-181 family 
were found in CEBPA-mutated cases and has been showed 
to correlate with treatment response and better clinical 
outcome in AML patients. Treatment of AML-blasts 
carrying CEBPA-mutations with lenalidomide sensitized 
AML cells to chemotherapy and increased CEBPA-p30 
protein levels and miR-181a expression [41]. 
To examine if the miRNA signatures given in 
Supplimentary Table 4 are characterized by distinct 
target gene patterns, thus reflecting disease biology, we 
performed the following analyses: we downloaded 289 
miRNAs from five miRNA-mRNA target prediction 
databases: microcosm, mirecords, mirtarbase and pita 
targetscan. Among the 47 unique miRNAs given in 
Table 3, only 25 were found in the miRNA-mRNA target 
prediction databases we downloaded (see Supplementary 
Table 3). To reliably predict miRNA target genes, we call 
a gene as the target of the miRNA under investigation if 
the prediction is reported at least in three databases.  It is 
known that a miRNA expression is inversely correlated 
with the expression of its targeted genes. To investigate 
if this prior knowledge holds in our dataset, we obtained 
mRNA expression dataset that were measured on the 
same samples24. Visualizations of the inverse correlation 
between miRNA and targeted genes were displayed 
in Supplementary Figure 1–58. While some genes 
behaved consistent with the prior assumption, i.e. inverse 
correlation, we also observed genes that violated the 
assumption. We believe this worth further investigation.
To sum up, (cyto)genetic aberrations groups have 
specific miRNA expression profiles both in pediatric 
and adult. In unsupervised, some patients with unknown 
underlying common genetic or molecular denominator 
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were clustered together. Further investigations focusing 
on the common factor in these clusters might reveal new 
subgroups of pediatric AML. Although relatively high 
classification results were obtained from the six aberration 
groups investigated in this study, they did not exceed 
the results from currently used methods, which limits 
its clinical applicability. We believe that the miRNAs 
signatures reported here spark future line of research 
as they may provide insights into important biological 
pathways involved in pediatric AML.
MATERIALS AND METHODS
Viably frozen diagnostic bone marrow or peripheral 
blood samples from 165 de novo pediatric AML cases were 
provided by the Dutch Childhood Oncology Group, the 
AML ‘Berlin-Frankfurt-Münster’ Study Group, the Czech 
Pediatric Hematology Group and the St. Louis Hospital 
in Paris, France. Samples represented the most common 
and relevant cytogenetic groups and were selected based 
on the availability of high-quality RNA. Informed consent 
was obtained from all patients, after Institutional Review 
Board approval, according to national law and regulations. 
Samples were enriched to contain at least 80% leukemic 
cells as previously described [23]. Routine analysis 
of recurrent non-random cytogenetic aberrations was 
performed by standard chromosome banding analysis, RT-
PCR, and split-signal FISH (MLL-rearrangements, inv(16)
(p13q22), t(8;21)(q22;q22), t(15;17)(q21;q22), t(7;12)
(q36;p13), t(8;16)(p11;p13), and NUP98-rearrangements) 
and hotspot mutations in genes (NPM1, CEBPA, FLT3-
ITD, NRAS, KRAS, PTPN11, c-KIT, and MLL-PTD) as 
described previously [24–30].
MicroRNA expression profiling was performed 
by Taqman® Array MicroRNA Cards v2.0 (Applied 
Biosystems, Foster City, CA, USA). Raw Ct-values were 
analyzed, summarized and exported using SDS 2.3 (Applied 
Biosystems). All further biostatistical analyses including 
quality control, aggregation of data, data normalization, and 
filtering were performed using R 2.11.1 [31].
Unsupervised hierarchical clustering of samples 
was performed using 563 miRNAs. These miRNAs 
were 6-fold higher or lower expressed compared to the 
geometric mean of the cohort in at least one patient sample 
(Pearson correlation and Ward distance) within the R 3.0.3 
statistical environment.
A classifier was constructed for the groups identified 
by unsupervised clustering with at least ten samples. We 
used the classification strategy described in Balgobind 
et al. [24]. Normalized adult AML data [42] was obtained 
from the last author. Due to difference in data generating 
platforms, only part of the 47 miRNA signatures were 
found in the adult AML dataset (See Table 3). During the 
validation, a classifier was trained using the pediatric AML 
data with only those overlapped miRNA signatures. Then, 
the trained classifier was applied to the adult AML dataset 
to quantify the prediction accuracy.
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